ARTICLE | Clinical News

Bavituximab: Preliminary Phase Ia data

June 12, 2006 7:00 AM UTC

Preliminary data from a Phase Ia trial in 28 patients showed that after a single dose of 1 mg/kg or 3 mg/kg Tarvacin, 50% of patients achieved a >75% reduction in serum HCV RNA with a maximum of a 97%...